{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-003966","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.599307+00:00","generated_at":"2026-06-19T21:35:04.110824+00:00","sec_items":["3.02","5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Palisade Bio promotes Robert McRae to COO, appoints J.D. Finley to Board","bullets":["Robert McRae appointed COO effective Feb 2, 2023; previously SVP of Operations and Strategic Development.","J.D. Finley (interim CEO/CFO) appointed to Board as Class III director, expanding board from 7 to 8.","Finley's base salary raised to $490K (from $440K) and target bonus increased to 45%, effective Oct 1, 2022.","Conditional equity grants to officers: 81,500 options ($2.40, 10yr), 59,500 RSUs, 68,700 PSUs; require shareholder approval.","PSUs vest 50% at $3.20 VWAP and 50% at $4.25 VWAP over 20 consecutive trading days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-003966","json":"https://secwatch.observer/filing/0001493152-23-003966.json","markdown":"https://secwatch.observer/filing/0001493152-23-003966.md","text":"https://secwatch.observer/filing/0001493152-23-003966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223003966/0001493152-23-003966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223003966/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:35:04.110824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07003344b0","claim":"Robert McRae was appointed as Chief Operating Officer at PALISADE BIO, INC..","evidence_excerpt":"On February 2, 2023, the Company appointed Robert McRae as the Company’s Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223003966/0001493152-23-003966-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"6f683f5095","claim":"J.D. Finley was appointed as Director at PALISADE BIO, INC..","evidence_excerpt":"On February 2, 2023, the Board appointed J.D. Finley to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223003966/0001493152-23-003966-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}